



NEWS RELEASE

## ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment

4/25/2013

SAN DIEGO, April 3, 2013 /PRNewswire/ -- RESMED INC. (NYSE: RMD) announced today that on Thursday, April 25, 2013, it will release its results for the third quarter and nine months of fiscal year 2013, ended March 31, 2013. A press release with ResMed's results will be issued after 1:00 p.m. US Pacific Time and the company will host a conference call and webcast to review its results, market trends, and future outlook.

(Logo: <http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO>)

The conference call is scheduled to begin at 1:30 p.m. US Pacific Time and will be webcast on ResMed's website at <http://investor.resmed.com>. Please go to this section of the website 5-10 minutes before the call and click on the icon for the "Q3 2013 results webcast." The online archive of the broadcast will be available approximately 30 minutes after the live call and will continue to be available for two weeks.

International conference call times will be:

---

9:30 p.m.  
6:30 a.m.

London  
Sydney, Australia (April 26, 2013)

**TO PARTICIPATE** in the conference call, please call one of the numbers below at least 10 minutes before the call

begins and identify yourself to the operator:

---

US:	847-585-4405
Outside US:	+1 847-585-4405
Conference Name:	Q3 2013 ResMed Inc. Results Conference Call
Participant Passcode:	34598681

The replay of the conference call will be available approximately 30 minutes after the call and will be accessible for two weeks at:

---

US:	630- 652-3042
Outside US:	+1 630-652-3042
Passcode:	34598681

ResMed is a global leader in the development, manufacturing, and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. Further information can be obtained by contacting Constance Bienfait at ResMed Inc. at +1 (858) 836-5971, or by visiting the company's website at [www.resmed.com](http://www.resmed.com).

SOURCE ResMed Inc.